Press Resease

Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug discovery and Development, Personalized medicine, Diagnostics, and Other Applications): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024

Published Date: 01-Oct-2018 Category: Biotechnology Report Format : PDF Pages: 140 Report Code: ZMR-2641 Status : Published

Global cancer biomarkers market expected to generate revenue of around USD 26,000 million by end of 2024, growing at a CAGR of around 13% between 2018 and 2024. Cancer biomarkers are perceptible substances, that are used as an indicator of the biological status of the tumor and hence they are used to analyze the prognostic and diagnostic stages of cancer.

Description

The report covers forecast and analysis for the cancer biomarkers market on a global and regional level. The study provides historic data of 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints for the cancer biomarkers market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer biomarkers market on a global level.

In order to give the users of this report a comprehensive view of the cancer biomarkers market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein biomarker type segment, cancer type segment, , and profiling technology segment are benchmarked based on their market size, growth rate, and general attractiveness.

Global Cancer Biomarkers Market

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new cancer type launch, agreements, partnerships, collaborations & joint ventures, research & development, cancer type, and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, product portfolio of various companies according to region.

The study provides a decisive view of the cancer biomarkers market by segmenting the market based on biomarker type segment, cancer type, and profiling technology, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on biomarker type the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies segment is further segmented as genomics, proteomics, and other omic technologies. Based on applications, the cancer biomarkers market segmented as drug discovery and development, personalized medicine, diagnostics, and other applications. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S., Rest of North America, U.K., Germany, France, Italy, Spain, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, Brazil, Rest of Latin America, GCC Countries, South Africa and Rest of Middle East and Africa. 

The report also includes detailed profiles of end players such as Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, Genomic Health, Inc.

This report segments the global cancer biomarkers market as follows:

Global Cancer Biomarkers Market: Biomarker Type Segment Analysis

  • Genetic Biomarkers 
  • Protein Biomarkers 
  • Other Cancer Biomarkers

Global Cancer Biomarkers Market: Cancer Type Segment Analysis

  • Breast Cancer 
  • Lung Cancer 
  • Prostate Cancer 
  • Colorectal Cancer 
  • Blood Cancer
  • Melanoma 
  • Ovarian Cancer
  • Liver Cancer
  • Stomach Cancer
  • Other Cancer Types 

Global Cancer Biomarkers Market: Profiling Technology Segment Analysis

  • Imaging technologies
  • Omic Technologies
    • Proteomics
    • Genomics
    • Other Omic technologies
  • Cytogenetics-Based Tests
  • Immunoassays

Global Cancer Biomarkers Market: Applications  Segment Analysis

  • Drug discovery and Development
  • Personalized medicine
  • Diagnostics
  • Others

Global Cancer Biomarkers Market: Regional Segment Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Cancer Biomarkers market, 2017 - 2024(USD Million)
    • 2.2. Global Cancer Biomarkers market: snapshot
  •  
  • Chapter 3. Cancer Biomarkers Market- Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Global Cancer Biomarkers market drivers: impact analysis
      • 3.2.2. Growing prevalence and incidence of various cancer types
      • 3.2.3. Technological Advancements in Cancer Diagnostics
      • 3.2.4. Growing Use of Cancer Biomarkers in Drug Discovery and Development
      • 3.2.5. Accuracy and reliability
      • 3.2.6. Rise in investment from government, public, and private sectors
    • 3.3. Market Restraints
      • 3.3.1. Global Cancer Biomarkers market restraints: impact analysis
      • 3.3.2. Unfavorable Reimbursement and Regulatory Scenario
      • 3.3.3. High Capital Investment
      • 3.3.4. Technical Issues Related to Sample Collection and Storage
    • 3.4. Opportunities
      • 3.4.1. Companion Diagnostics
      • 3.4.2. Personalized Medicine
      • 3.4.3. Significant unmet need in cancer diagnosis
      • 3.4.4. Opportunities in emerging economies
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. Threat from new entrants
      • 3.5.4. Threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis, by Biomarker Type segment
      • 3.6.2. Market attractiveness analysis, by Cancer Type segment
      • 3.6.3. Market attractiveness analysis, by Profiling Technology segment
      • 3.6.4. Market attractiveness analysis, by Applications segment
      • 3.6.5. Market attractiveness analysis, by regional segment
  •  
  • Chapter 4. Global Cancer Biomarkers Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Cancer Biomarkers market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New therapy launch
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  •  
  • Chapter 5. Global Cancer Biomarkers Market- Biomarker Type Segment Analysis
    • 5.1. Global Cancer Biomarkers market: product overview
      • 5.1.1. Global Cancer Biomarkers market revenue share, by Biomarker Type, 2017 and 2024
    • 5.2. Genetic Biomarkers
      • 5.2.1. Global Cancer Biomarkers market for Genetic Biomarkers, 2017 - 2024(USD Million)
    • 5.3. Protein Biomarkers
      • 5.3.1. Global Cancer Biomarkers market for Protein Biomarkers, 2017 - 2024 (USD Million)
    • 5.4. Other Biomarkers
      • 5.4.1. Global Cancer Biomarkers market for Other Biomarkers, 2017 - 2024 (USD Million)
  •  
  • Chapter 6. Global Cancer Biomarkers Market- Cancer Type Segment Analysis
    • 6.1. Global Cancer Biomarkers market: Cancer Type overview
      • 6.1.1. Global Cancer Biomarkers market revenue share, by Cancer Type, 2017 and 2024
    • 6.2. Breast Cancer
      • 6.2.1. Global Cancer Biomarkers market for Breast Cancer, 2017 - 2024 (USD Million)
    • 6.3. Lung Cancer
      • 6.3.1. Global Cancer Biomarkers market for Lung Cancer, 2017 - 2024 (USD Million)
    • 6.4. Prostate Cancer
      • 6.4.1. Global Cancer Biomarkers market for Prostate Cancer,2017 - 2024(USD Million)
    • 6.5. Colorectal Cancer
      • 6.5.1. Global Cancer Biomarkers market for Colorectal Cancer,2017 - 2024(USD Million)
    • 6.6. Blood Cancer
      • 6.6.1. Global Cancer Biomarkers market for Blood Cancer,2017 - 2024(USD Million)
    • 6.7. Melanoma
      • 6.7.1. Global Cancer Biomarkers market for Melanoma,2017 - 2024(USD Million)
    • 6.8. Ovarian Cancer
      • 6.8.1. Global Cancer Biomarkers market for Ovarian Cancer,2017 - 2024(USD Million)
    • 6.9. Liver Cancer
      • 6.9.1. Global Cancer Biomarkers market for Liver Cancer,2017 - 2024(USD Million)
    • 6.10. Stomach Cancer
      • 6.10.1. Global Cancer Biomarkers market for Stomach Cancer,2017 - 2024(USD Million)
    • 6.11. Other Cancer Type
      • 6.11.1. Global Cancer Biomarkers market for Other Cancer Type,2017 - 2024(USD Million)
  •  
  • Chapter 7. Global Cancer Biomarkers Market- Profiling Technology Segment Analysis
    • 7.1. Global Cancer Biomarkers market: Profiling Technology type overview
      • 7.1.1. Global Cancer Biomarkers market revenue share, by Profiling Technology, 2017 and 2024
    • 7.2. Imaging technologies
      • 7.2.1. Global Cancer Biomarkers market for Imaging technologies, 2017 - 2024 (USD Million)
    • 7.3. Omic Technologies
      • 7.3.1. Global Cancer Biomarkers market for Omic Technologies, 2017 - 2024 (USD Million)
    • 7.4. Cytogenetics-Based Tests
      • 7.4.1. Global Cancer Biomarkers market for Cytogenetics-Based Tests,2017 - 2024(USD Million)
    • 7.5. Immunoassays
      • 7.5.1. Global Cancer Biomarkers market for Immunoassays,2017 - 2024(USD Million)
  •  
  • Chapter 8. Global Cancer Biomarkers Market- Applications Segment Analysis
    • 8.1. Global Cancer Biomarkers market: Applications type overview
      • 8.1.1. Global Cancer Biomarkers market revenue share, by Applications, 2017 and 2024
    • 8.2. Drug discovery and Development
      • 8.2.1. Global Cancer Biomarkers market for Drug Discovery and Development, 2017 - 2024 (USD Million)
    • 8.3. Personalized Medicine
      • 8.3.1. Global Cancer Biomarkers market for Personalized Medicine, 2017 - 2024 (USD Million)
    • 8.4. Diagnostics
      • 8.4.1. Global Cancer Biomarkers market for Diagnostics,2017 - 2024(USD Million)
    • 8.5. Other Applications
      • 8.5.1. Global Cancer Biomarkers market for Other Applications,2017 - 2024(USD Million)
  •  
  • Chapter 9. Global Cancer Biomarkers Market- Regional Segment Analysis
    • 9.1. Global Cancer Biomarkers market: regional overview
      • 9.1.1. Global Cancer Biomarkers market revenue share, by region, 2017 and 2024
    • 9.2. North America
      • 9.2.1. North America Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
      • 9.2.2. North America Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
      • 9.2.3. North America Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
      • 9.2.4. North America Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.2.5. U.S.
        • 9.2.5.1. U.S. Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.2.5.2. U.S. Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.2.5.3. U.S. Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.2.5.4. U.S. Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.2.6. Rest of North America
        • 9.2.6.1. Rest of North America Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.2.6.2. Rest of North America Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.2.6.3. Rest of North America Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.2.6.4. Rest of North America Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
    • 9.3. Europe
      • 9.3.1. Europe Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
      • 9.3.2. Europe Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
      • 9.3.3. Europe Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
      • 9.3.4. Europe Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.5. U.K.
        • 9.3.5.1. U.K. Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024 (USD Million)
        • 9.3.5.2. U.K. Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024 (USD Million)
        • 9.3.5.3. U.K. Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.5.4. U.K. Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.6. Germany
        • 9.3.6.1. Germany Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.3.6.2. Germany Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.3.6.3. Germany Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.6.4. Germany Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.7. France
        • 9.3.7.1. France Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.3.7.2. France Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.3.7.3. France Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.7.4. France Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.8. Italy
        • 9.3.8.1. Italy Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.3.8.2. Italy Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.3.8.3. Italy Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.8.4. Italy Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.9. Spain
        • 9.3.9.1. Spain Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.3.9.2. Spain Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.3.9.3. Spain Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.9.4. Spain Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.3.10. Rest of Europe
        • 9.3.10.1. Rest of Europe Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.3.10.2. Rest of Europe Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.3.10.3. Rest of Europe Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.3.10.4. Rest of Europe Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
    • 9.4. Asia Pacific
      • 9.4.1. Asia Pacific Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024 (USD Million)
      • 9.4.2. Asia Pacific Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
      • 9.4.3. Asia Pacific Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
      • 9.4.4. Asia Pacific Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.4.5. China
        • 9.4.5.1. China Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.4.5.2. China Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.4.5.3. China Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.4.5.4. China Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.4.6. Japan
        • 9.4.6.1. Japan Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.4.6.2. Japan Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.4.6.3. Japan Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.4.6.4. Japan Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.4.7. India
        • 9.4.7.1. India Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.4.7.2. India Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.4.7.3. India Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.4.7.4. India Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.4.8. Southeast Asia
        • 9.4.8.1. Southeast Asia Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.4.8.2. Southeast Asia Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.4.8.3. Southeast Asia Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.4.8.4. Southeast Asia Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.4.9. Rest of Asia Pacific
        • 9.4.9.1. Rest of Asia Pacific Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.4.9.2. Rest of Asia Pacific Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.4.9.3. Rest of Asia Pacific Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.4.9.4. Rest of Asia Pacific Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
    • 9.5. Latin America
      • 9.5.1. Latin America Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
      • 9.5.2. Latin America Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
      • 9.5.3. Latin America Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
      • 9.5.4. Latin America Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.5.5. Brazil
        • 9.5.5.1. Brazil Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.5.5.2. Brazil Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.5.5.3. Brazil Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.5.5.4. Brazil Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.5.6. Rest of Latin America
        • 9.5.6.1. Rest of Latin America Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.5.6.2. Rest of Latin America Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.5.6.3. Rest of Latin America Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.5.6.4. Rest of Latin America Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
    • 9.6. Middle East and Africa
      • 9.6.1. Middle East and Africa Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
      • 9.6.2. Middle East and Africa Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
      • 9.6.3. Middle East and Africa Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
      • 9.6.4. Middle East and Africa Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.6.5. GCC Countries
        • 9.6.5.1. GCC Countries Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.6.5.2. GCC Countries Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.6.5.3. GCC Countries Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.6.5.4. GCC Countries Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
      • 9.6.6. Rest of Middle East and Africa
        • 9.6.6.1. Rest of Middle East and Africa Cancer Biomarkers market revenue, by Biomarker Type, 2017 - 2024(USD Million)
        • 9.6.6.2. Rest of Middle East and Africa Cancer Biomarkers market revenue, by Cancer Type, 2017 - 2024(USD Million)
        • 9.6.6.3. Rest of Middle East and Africa Cancer Biomarkers market revenue, by Profiling Technology, 2017 - 2024(USD Million)
        • 9.6.6.4. Rest of Middle East and Africa Cancer Biomarkers market revenue, by Applications, 2017 - 2024(USD Million)
  •  
  • Chapter 10. Company Profile
    • 10.1. Thermo Fisher Scientific Inc.
      • 10.1.1. Overview
      • 10.1.2. Financials
      • 10.1.3. Product portfolio
      • 10.1.4. Business strategy
      • 10.1.5. Recent developments
    • 10.2. Abbott Laboratories
      • 10.2.1. Overview
      • 10.2.2. Financials
      • 10.2.3. Product portfolio
      • 10.2.4. Business strategy
      • 10.2.5. Recent developments
    • 10.3. F. Hoffmann-La Roche Ltd
      • 10.3.1. Overview
      • 10.3.2. Financials
      • 10.3.3. Product portfolio
      • 10.3.4. Business strategy
      • 10.3.5. Recent developments
    • 10.4. Agilent Technologies
      • 10.4.1. Overview
      • 10.4.2. Financials
      • 10.4.3. Product portfolio
      • 10.4.4. Business strategy
      • 10.4.5. Recent developments
    • 10.5. QIAGEN
      • 10.5.1. Overview
      • 10.5.2. Financials
      • 10.5.3. Product portfolio
      • 10.5.4. Business strategy
      • 10.5.5. Recent developments
    • 10.6. Illumina, Inc.,
      • 10.6.1. Overview
      • 10.6.2. Financials
      • 10.6.3. Product portfolio
      • 10.6.4. Business strategy
      • 10.6.5. Recent developments
    • 10.7. QIAGEN
      • 10.7.1. Overview
      • 10.7.2. Financials
      • 10.7.3. Product portfolio
      • 10.7.4. Business strategy
      • 10.7.5. Recent developments
    • 10.8. Sino Biological Inc.
      • 10.8.1. Overview
      • 10.8.2. Financials
      • 10.8.3. Product portfolio
      • 10.8.4. Business strategy
      • 10.8.5. Recent developments
    • 10.9. Merck & Co., Inc.
      • 10.9.1. Overview
      • 10.9.2. Financials
      • 10.9.3. Product portfolio
      • 10.9.4. Business strategy
      • 10.9.5. Recent developments
    • 10.10. Novartis AG
      • 10.10.1. Overview
      • 10.10.2. Financials
      • 10.10.3. Product portfolio
      • 10.10.4. Business strategy
      • 10.10.5. Recent developments
    • 10.11. Hologic, Inc.
      • 10.11.1. Overview
      • 10.11.2. Financials
      • 10.11.3. Product portfolio
      • 10.11.4. Business strategy
      • 10.11.5. Recent developments
    • 10.12. bioMérieux SA
      • 10.12.1. Overview
      • 10.12.2. Financials
      • 10.12.3. Product portfolio
      • 10.12.4. Business strategy
      • 10.12.5. Recent developments
    • 10.13. Genomic Health, Inc.
      • 10.13.1. Overview
      • 10.13.2. Financials
      • 10.13.3. Product portfolio
      • 10.13.4. Business strategy
      • 10.13.5. Recent developments

Methodology

Free Analysis

Cancer biomarkers are molecules which are released in the presence of a tumor or show a particular indication in the body related to the presence of cancer. These are molecular substances or a physical condition that shows the presence of cancer cells in the body. These kinds of molecules are usually found in the urine, tissues, blood, serum, and other body fluids. Cancer biomarkers are noticeable substances that can be utilized as a sign of biological state for tumor, therefore it can be utilized to prognostic stages of cancer and analyze test as well.

The global cancer biomarkers market is segmented as biomarker type, cancer type, profiling technology, applications, and by geography. Based on biomarker type, the global cancer biomarkers market is segmented as genetic biomarkers, protein biomarkers, and other biomarkers. Based on cancer type, the market is segmented as breast cancer, colorectal cancer, lung cancer, prostate cancer, blood cancer, melanoma, ovarian cancer, liver cancer, stomach cancer, and other cancer types. By profiling technology, the cancer market is further segmented as imaging technologies, omic technologies, cytogenetics-based tests, and immunoassays. The omic technologies segment is further segmented as genomics, proteomics, and other omic technologies. Based on applications, the cancer biomarkers market is segmented as drug discovery and development, personalized medicine, diagnostics, and other applications.

Global Cancer Biomarkers Market

By geography, the global cancer biomarkers market is segmented into North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. North America dominated the cancer biomarkers market globally in 2017 and is expected to remain dominant over the forecast period. The high prevalence of cancer, large demand for technically advanced diagnostics for cancer, high government support for diagnostics and treatment of chronic diseases are the key factor contributing towards the high share of North America in the global cancer biomarkers market. In terms of growth rate, Asia Pacific is anticipated to register high growth in the global cancer biomarkers market. The growing government support to avail advanced diagnostics tools and large patient pool, are the main factors expected to propel the growth of the cancer biomarkers market in the region. 

Some of the key players in the cancer biomarkers market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Agilent Technologies, QIAGEN, Illumina, Inc., QIAGEN, Sino Biological Inc., Merck & Co., Inc., Novartis AG, Hologic, Inc., bioMérieux SA, Genomic Health, Inc., among others. The increasing investment by the key players in research and development activities to enhance the product portfolio is expected to propel the growth of the cancer biomarkers market in the coming future. For instance, in November 2016, the Thermo Fisher Scientific announced four new additions to its product portfolio for cancer research of multi-biomarker targeted assays. The new development includes the Oncomine Immune Response Research Assay, which is designed to cross-examine microenvironment of the tumor and allow identification of prognostic biomarkers for immunotherapy clinical research trials. 

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com